Corvus Pharmaceuticals (CRVS) Total Non-Current Liabilities (2015 - 2026)
Corvus Pharmaceuticals (CRVS) recorded quarterly Total Non-Current Liabilities of $143000.0 in Q1 2026, down 37.55% quarter-over-quarter from $229000.0 in Q4 2025, and down 71.57% on a YoY basis from $503000.0 in Q1 2025.
Corvus Pharmaceuticals (CRVS) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $143000.0 for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 71.57% year-over-year to $143000.0; the TTM figure through Mar 2026 stood at $143000.0 (down 71.57% YoY), while the FY2025 annual figure was $229000.0, down 61.38% from the prior year.
- Total Non-Current Liabilities was $143000.0 for Q1 2026 at Corvus Pharmaceuticals, down from $229000.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.0 million in Q2 2022 to a low of $143000.0 in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $619875.0 across 5 years, with a median of $610000.0 in 2024.
- The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities soared 838.1% in 2022, then slumped 71.57% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $985000.0 in 2022, then sank by 34.21% to $648000.0 in 2023, then dropped by 8.49% to $593000.0 in 2024, then plunged by 61.38% to $229000.0 in 2025, then plunged by 37.55% to $143000.0 in 2026.
- The last three Total Non-Current Liabilities figures came in at $143000.0 (Q1 2026), $229000.0 (Q4 2025), and $321000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 42,980.09 |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 64.76 Mn |
| 10 | Corvus Pharmaceuticals | 1.01 Bn | 771.25 Mn | - | 143,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 143,000.00 |
| Dec 31, 2025 | 229,000.00 |
| Sep 30, 2025 | 321,000.00 |
| Jun 30, 2025 | 414,000.00 |
| Mar 31, 2025 | 503,000.00 |
| Dec 31, 2024 | 593,000.00 |
| Sep 30, 2024 | 625,000.00 |
| Jun 30, 2024 | 531,000.00 |
| Mar 31, 2024 | 595,000.00 |
| Dec 31, 2023 | 648,000.00 |
| Sep 30, 2023 | 686,000.00 |
| Jun 30, 2023 | 773,000.00 |
| Mar 31, 2023 | 903,000.00 |
| Dec 31, 2022 | 985,000.00 |
| Sep 30, 2022 | 945,000.00 |
| Jun 30, 2022 | 1.02 Mn |
| Dec 31, 2021 | 105,000.00 |
| Dec 31, 2018 | 7.03 Mn |
| Sep 30, 2018 | 7.75 Mn |
| Jun 30, 2018 | 9.78 Mn |